Online inquiry

IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12563MR)

This product GTTS-WQ12563MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets Felcat NGF gene. The antibody can be applied in Feline osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Felinized
RefSeq XM_004001117.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100144611
UniProt ID A0A337SBN0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12563MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6127MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA COR-001
GTTS-WQ1403MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ACA125
GTTS-WQ4515MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ10164MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ14762MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ4061MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ1003MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-383
GTTS-WQ14812MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SGN-70
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW